All Alzheimer's articles
-
ResearchLow lithium levels linked to Alzheimer’s
Immune cells’ ability to degrade amyloid-beta peptides restored in mice treated with lithium salt
-
OpinionWelcome to the MegaPharm target selection and project resourcing meeting
Overheard recently in a seminar room near you…
-
BusinessEurope reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
-
OpinionLetters: September 2024
Readers discuss antidepressants, industrial disasters and what Humphry Davy inhaled
-
OpinionBeing wrong is almost inevitable
On the tightrope of expressing your opinion, you always risk looking a fool
-
ResearchNew mechanism identified that is potentially linked to very early stages of Alzheimer’s
Understanding role of fragments of amyloid protein could lead to novel therapies for the disease
-
FeatureHow microbes influence our brain health
Our gut microbiome has been linked to conditions such as Parkinson’s and Alzheimer’s. Anthony King reports on the connections
-
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
ResearchRare medical transmission of Alzheimer’s disease from donor to patient discovered
Human growth hormone extracted from cadavers passed disease protein to at least five people
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
OpinionMoving beyond protein structure
Efforts to understand how intrinsically disordered regions interact have produced a variety of answers
-
OpinionLetters: September 2023
Readers estimate the contribution of lithium mining on power consumption, consider Alzheimer’s antibody therapies and more
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
ResearchTell-tale protein fragment discovered in Alzheimer’s patients could be basis for blood test
Tau protein fragment could track progress of the disease
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
BusinessSecond Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
BusinessAlzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?